Xadago (safinamide) vs Nourianz/Nouriast (istradefylline)
Xadago (safinamide) vs Nourianz/Nouriast (istradefylline)
Xadago (safinamide) and Nourianz/Nouriast (istradefylline) are both adjunctive treatments for Parkinson's disease but they work through different mechanisms. Xadago acts as a monoamine oxidase-B (MAO-B) inhibitor, which helps increase dopamine levels in the brain, potentially improving motor symptoms and reducing 'off' time when a patient's medication is not working well. In contrast, Nourianz/Nouriast is an adenosine A2A receptor antagonist, which modulates the neurotransmitter activity in a way that also aims to improve motor symptoms without directly increasing dopamine levels, offering an alternative for those who may not tolerate or respond to MAO-B inhibitors like Xadago.
Difference between Xadago and Nourianz/Nouriast
| Metric | Xadago (safinamide) | Nourianz/Nouriast (istradefylline) |
|---|---|---|
| Generic name | Safinamide | Istradefylline |
| Indications | Adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes | Adjunctive treatment to levodopa/carbidopa in adults with Parkinson's disease experiencing "off" episodes |
| Mechanism of action | MAO-B inhibitor, increases dopamine levels and has glutamate modulating properties | Adenosine A2A receptor antagonist |
| Brand names | Xadago | Nourianz, Nouriast |
| Administrative route | Oral | Oral |
| Side effects | Insomnia, nausea, dyskinesia, dizziness, falls | Dyskinesia, dizziness, constipation, nausea, hallucination, insomnia |
| Contraindications | Severe hepatic impairment, patients with pheochromocytoma, tyramine-induced hypertensive crisis, concomitant use of other MAO inhibitors or opioids | None known |
| Drug class | MAO-B inhibitor | Adenosine receptor antagonist |
| Manufacturer | Newron Pharmaceuticals | Kyowa Kirin |
Efficacy
Xadago (Safinamide) in Parkinson's Disease Treatment
Xadago (safinamide) is a medication that has been approved for use as an add-on treatment for individuals with Parkinson's Disease who are currently taking levodopa/carbidopa and experiencing "off" episodes. These are periods when the effectiveness of levodopa wears off, and symptoms of Parkinson's Disease, such as tremor and difficulty moving, return. Safinamide works by inhibiting monoamine oxidase B (MAO-B) and dopamine reuptake, which leads to increased levels of dopamine in the brain, potentially improving motor function.
Clinical trials have demonstrated the efficacy of safinamide in reducing "off" time in patients with Parkinson's Disease. Studies have shown that patients taking safinamide experience an improvement in their daily "on" time without troublesome dyskinesia. This improvement in "on" time is associated with better control over motor symptoms and an enhanced quality of life for patients. Safinamide has also been shown to have a beneficial effect on mood and motor complications, which are common issues for patients with Parkinson's Disease.
Nourianz/Nouriast (Istradefylline) in Parkinson's Disease Management
Nourianz (in the United States) or Nouriast (in Japan) with the active ingredient istradefylline, is another medication approved for the treatment of Parkinson's Disease. It is specifically indicated as an add-on treatment to carbidopa/levodopa therapy in adult patients experiencing "off" episodes. Istradefylline is an adenosine A2A receptor antagonist, and its mechanism of action is thought to involve the modulation of the neurotransmitters in the brain that affect motor function.
The efficacy of istradefylline has been established through multiple clinical trials. These studies have indicated that istradefylline, when added to a stable dose of carbidopa/levodopa, reduces the amount of "off" time and increases "on" time without worsening dyskinesia in patients with Parkinson's Disease. The improvement in "on" time is particularly beneficial as it corresponds to periods when the patient has better control over movement and experiences fewer symptoms of Parkinson's Disease.
Regulatory Agency Approvals
Xadago
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
Nourianz/Nouriast
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Access Xadago or Nourianz/Nouriast today
If Xadago or Nourianz/Nouriast are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us